Dermapharm Holding SE

As of March 31, 2026, Dermapharm Holding SE has 666.46M shares outstanding.

These figures are as of March 31, 2026. The price-to-sales ratio is 5.59, and the price-to-book ratio stands at 3.92.

These figures are as of March 31, 2026. The EV/Sales ratio of 4.93 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative.

As of March 31, 2026, Dermapharm Holding SE maintains a current ratio of 1.01, meaning it holds 1.0x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 3.50, indicating elevated leverage, while an interest coverage ratio of -112.94 demonstrates limited ability to service its debt obligations.

Over the twelve months ended March 31, 2026, Dermapharm Holding SE posted a negative return on equity (ROE) of -57.63, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -2.76, reflecting losses generated across the asset base. Inventory turnover of 2.99 indicates how many times Dermapharm Holding SE sells and replaces its inventory over a year, a key working capital efficiency ratio.

As of the close on June 3, 2026, Dermapharm Holding SE's stock has declined approximately 3.04% over the past 52 weeks. The 50-day moving average sits at 0.20, while the 200-day moving average is 0.19.

Over the twelve months ended March 31, 2026, Dermapharm Holding SE posted a gross margin of 58.37, reflecting its pricing power and cost economics. The operating margin of -74.74 and net profit margin of -113.23 provide insight into operational efficiency.

These figures cover the twelve months ended March 31, 2026. Free cash flow yield is negative at -6.60: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield reaches 0.94, combining dividends paid with share buybacks and debt reduction for a fuller picture of capital returned to Dermapharm Holding SE shareholders.

As of March 31, 2026, Dermapharm Holding SE has an Altman Z-Score of -0.23, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.